PMID: 3766527Nov 1, 1986Paper

The mechanisms of sulfonylurea-induced immune hemolysis: case report and review of the literature

American Journal of Hematology
J A Kopicky, C H Packman


Chlorpropamide, a sulfonylurea antidiabetic drug, was found to be the etiologic agent in a patient with immune hemolytic anemia. Hemolysis was severe, and ceased promptly when the drug was discontinued. The direct antiglobulin test was positive for complement, and the indirect antiglobulin test was also positive when the drug, patient serum, and fresh serum complement were all present. In this patient, and in four other patients described in the literature, hemolysis was mediated by the immune complex mechanism. In reports of two other patients taking a sulfonylurea drug, a milder form of hemolysis was mediated by the hapten mechanism. Sulfonylurea drugs are widely used. Since immune complex-mediated hemolysis in these patients is dramatic, it is not likely to be missed. However, the slower, milder hemolysis mediated by the hapten mechanism may be more common than is realized. Such patients may have only mild anemia and a near-normal reticulocyte count, making the diagnosis difficult. It is thus important to consider drug-immune hemolysis in patients who become anemic while taking sulfonylurea drugs.


Feb 1, 1977·Diabetes·P MalacarneG Zavagli
Mar 18, 1972·British Medical Journal·G W BirdJ Wingham
Oct 22, 1970·The New England Journal of Medicine·G L LogueW F Rosse
Dec 1, 1984·Drug Intelligence & Clinical Pharmacy·R OrY Matzner
Jan 1, 1981·Postgraduate Medical Journal·B SaffouriN Felber
Nov 1, 1981·Vox Sanguinis·J R Duran-SuarezJ Triginer

❮ Previous
Next ❯


Jun 1, 1989·Blood Reviews·S Ammus, A A Yunis

❮ Previous
Next ❯

Related Concepts

Related Feeds


Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.

© 2021 Meta ULC. All rights reserved